Moderna’s 0.96% Gain on 220M Volume (Rank 482) Driven by Kyoto Conference Debut of Rare Disease mRNA Trials

– Moderna’s stock rose 0.96% on 9/4/2025 amid 220M trading volume, driven by upcoming Kyoto conference data on rare disease mRNA therapies.

– The biotech firm will debut interim trial data for propionic acidemia, methylmalonic acidemia, and GSD1a at its first scientific conference presentations on these conditions.

– These presentations highlight Moderna’s expanding mRNA pipeline for rare metabolic disorders, aligning with its strategy to broaden therapeutic applications through clinical trials.